<?xml version="1.0" encoding="UTF-8"?>
<p>An overview of the current status of approval for nanopharmaceuticals can be found in the literature (
 <xref rid="B22" ref-type="bibr">22</xref>, 
 <xref rid="B23" ref-type="bibr">23</xref>) (
 <xref rid="T1" ref-type="table">Table 1</xref>). In general, all of the listed nanopharmaceuticals fall into the sub-categories of NBCDs mentioned before. Meanwhile, European (both EMA and national agencies, according to selected MA procedures) and FDA regulatory paths are different, bringing legal complexity and regulatory diversity for the submission strategies in the two different regions (
 <xref rid="B24" ref-type="bibr">24</xref>) (
 <xref ref-type="fig" rid="F1">Figures 1</xref>, 
 <xref ref-type="fig" rid="F2">2</xref>).
</p>
